S&P 500   3,926.26 (-0.38%)
DOW   33,538.91 (-0.17%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
S&P 500   3,926.26 (-0.38%)
DOW   33,538.91 (-0.17%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
S&P 500   3,926.26 (-0.38%)
DOW   33,538.91 (-0.17%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
S&P 500   3,926.26 (-0.38%)
DOW   33,538.91 (-0.17%)
QQQ   280.61 (-0.38%)
AAPL   140.25 (-1.86%)
MSFT   243.95 (-0.48%)
META   114.07 (-0.04%)
GOOGL   95.17 (-1.87%)
AMZN   88.17 (-0.09%)
TSLA   173.14 (-3.71%)
NVDA   160.61 (+0.46%)
NIO   12.64 (-4.53%)
BABA   88.86 (-2.83%)
AMD   70.15 (-0.17%)
T   19.28 (+0.57%)
MU   53.66 (-0.04%)
CGC   3.28 (-9.14%)
F   13.15 (-0.98%)
GE   85.02 (-0.30%)
DIS   92.15 (-0.15%)
AMC   6.08 (-9.93%)
PYPL   74.41 (+3.02%)
PFE   50.31 (+1.21%)
NFLX   307.36 (+0.59%)
NASDAQ:EPZM

Epizyme - EPZM Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$1.47
$1.47
50-Day Range
$1.47
$1.52
52-Week Range
$0.41
$5.80
Volume
7,960 shs
Average Volume
3.23 million shs
Market Capitalization
$247.44 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.00

Epizyme MarketRank™ Forecast

Analyst Rating
Hold
2.25 Rating Score
Upside/​Downside
104.1% Upside
$3.00 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
-1.07
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.34) to ($1.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.33 out of 5 stars

Medical Sector

278th out of 1,027 stocks

Pharmaceutical Preparations Industry

118th out of 503 stocks

EPZM stock logo

About Epizyme (NASDAQ:EPZM) Stock

Epizyme, Inc., a commercial-stage biopharmaceutical company, discovers, develops, and commercializes novel epigenetic medicines for patients with cancer and other diseases in the United States. The company offers Tazemetostat for the treatment of metastatic or locally advanced epithelioid sarcoma for adults and pediatric patients. It also develops R-CHOP in front-line patients with high risk diffuse large B-cell lymphoma; and PARP inhibitor in patients with PARPi-resistant solid tumors, such as castration-resistant prostate cancer, small cell lung cancer, and others. In addition, the company develops Tazemetostat in patients with INI1-negative tumors in adults and pediatrics; PRMT5 inhibitor for patients with solid tumors; and PRMT1 inhibitor. It has collaboration agreements with Roche Molecular Systems, Inc.; Lymphoma Academic Research Organization; Eisai Co. Ltd.; HUTCHMED (China) Limited; and Roche Sequencing Solutions, Inc. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Stock News Headlines

Epizyme: Q2 Earnings Insights - Benzinga
Epizyme: Q2 Earnings Snapshot
Epizyme shares soar 60% on acquisition news
See More Headlines

Receive EPZM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Epizyme and its competitors with MarketBeat's FREE daily newsletter.

EPZM Company Calendar

Last Earnings
11/09/2021
Today
12/07/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EPZM
Employees
250
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+104.1%
Consensus Rating
Hold
Rating Score (0-4)
2.25
Research Coverage
4 Analysts

Profitability

Net Income
$-251,120,000.00
Net Margins
-391.90%
Pretax Margin
-391.80%

Debt

Sales & Book Value

Annual Sales
$37.43 million
Book Value
($0.54) per share

Miscellaneous

Free Float
128,968,000
Market Cap
$247.44 million
Optionable
Optionable
Beta
-0.41

Key Executives

  • Mr. Grant C. Bogle (Age 64)
    Pres, CEO, Principal Financial Officer & Director
    Comp: $923.32k
  • Dr. Jeffery L. Kutok M.D. (Age 55)
    Ph.D., Chief Scientific Officer
    Comp: $646.13k
  • Dr. H. Robert Horvitz
    Co-Founder & Chairman of the Scientific Advisory Board
  • Dr. Yi Zhang
    Scientific Co-Founder & Member of The Scientific Advisory Board
  • Mr. Jerald Korn J.D. (Age 43)
    Chief Operating Officer
  • Mr. Joseph Beaulieu (Age 41)
    Sr. VP, Head of Fin., Controller, Treasurer & Principal Accounting Officer
  • Mr. Craig West CFA
    VP of Investor Relations
  • Mr. John F. Weidenbruch (Age 61)
    Sr. VP, Gen. Counsel & Sec.
  • Ms. Tanja Weber
    Chief Bus. Officer
  • Dr. Mark A. De Rosch Ph.D. (Age 58)
    Chief Regulatory Officer













EPZM Stock - Frequently Asked Questions

Should I buy or sell Epizyme stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Epizyme in the last year. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EPZM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EPZM, but not buy additional shares or sell existing shares.
View EPZM analyst ratings
or view top-rated stocks.

What is Epizyme's stock price forecast for 2023?

4 analysts have issued 12-month price targets for Epizyme's stock. Their EPZM share price forecasts range from $1.50 to $6.00. On average, they anticipate the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 104.1% from the stock's current price.
View analysts price targets for EPZM
or view top-rated stocks among Wall Street analysts.

How were Epizyme's earnings last quarter?

Epizyme, Inc. (NASDAQ:EPZM) issued its quarterly earnings data on Tuesday, November, 9th. The biopharmaceutical company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.48) by $0.16. The biopharmaceutical company had revenue of $5.20 million for the quarter, compared to analysts' expectations of $8.65 million. Epizyme had a negative trailing twelve-month return on equity of 2,459.33% and a negative net margin of 391.90%. Epizyme's revenue for the quarter was up 45.8% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.55) EPS.

What other stocks do shareholders of Epizyme own?
What is Epizyme's stock symbol?

Epizyme trades on the NASDAQ under the ticker symbol "EPZM."

Who are Epizyme's major shareholders?

Epizyme's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Citadel Advisors LLC (0.00%) and Group One Trading L.P. (0.00%). Insiders that own company stock include Carl Goldfischer, David M Mott, Jeffery Kutok, Joseph Beaulieu, Matthew Ros, Pablo G Legorreta, Paolo Tombesi, Robert B Bazemore, Robert B Bazemore and Shefali Agarwal.
View institutional ownership trends
.

What is Epizyme's stock price today?

One share of EPZM stock can currently be purchased for approximately $1.47.

How much money does Epizyme make?

Epizyme (NASDAQ:EPZM) has a market capitalization of $247.44 million and generates $37.43 million in revenue each year. The biopharmaceutical company earns $-251,120,000.00 in net income (profit) each year or ($1.72) on an earnings per share basis.

How many employees does Epizyme have?

The company employs 250 workers across the globe.

How can I contact Epizyme?

Epizyme's mailing address is 400 TECHNOLOGY SQUARE, CAMBRIDGE MA, 02139. The official website for the company is www.epizyme.com. The biopharmaceutical company can be reached via phone at (617) 229-5872, via email at monique@thrustsc.com, or via fax at 617-349-0707.

This page (NASDAQ:EPZM) was last updated on 12/7/2022 by MarketBeat.com Staff